Open-label Pharmacokinetic Study of Iron Isomaltoside 1000 (Monofer®) Administered by 500 mg IV Bolus Injection or 1000 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia (CIA)

• Status: Completed
• Trial end date: 2012-07-01

Summary

The purpose of this study is to assess the pharmakokinetic properties of higher doses (500 mg and 1000 mg) of Monofer(R)in patients suffering from non-hematological malignancies with Chemotherapy induced anaemia.

• Phase: Phase 1

Details

• Lead Sponsor: Pharmacosmos A/S
• Treatments: Ferric Compounds; Iron; Iron isomaltoside 1000